María Bucci-Muñoz

María Bucci-Muñoz

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2020 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
MSM. Semeniuk
M. Semeniuk
LCL. I. Ceré
L. I. Ceré
NCN. Ciriaci
N. Ciriaci
MBMaría Bucci-Muñoz
María Bucci-Muñoz
Silvina Stella Maris VillanuevaSilvina Stella Maris Villanueva
Silvina Stella Maris Villanueva
MRMaría Laura Ruiz
María Laura Ruiz

27 July 2023 in Life
Verified
Journal Article
Open access
PDF file
MBMaría Bucci-Muñoz
María Bucci-Muñoz
AGAldana Magalí Gola
Aldana Magalí Gola
Juan Pablo RigalliJuan Pablo Rigalli
Juan Pablo Rigalli
MCMaría Paula Ceballos
María Paula Ceballos
MRMaría Laura Ruiz
María Laura Ruiz
Cancer multidrug resistance (MDR) is one of the main mechanisms contributing to therapy failure and mortality. Overexpression of drug transporters of the ABC family (ATP-binding cassette) is a major cause of MDR. Extracellular vesicles (EVs) are nanoparticles released by most cells of the organism involved in cell–cell communication. Their cargo mainly comprises, proteins, nucleic acids, and lipids, which are transferred from a donor cell to a target cell and lead to phenotypical changes. In this article, we review the scientific evidence addressing the regulation of ABC transporters by EV-mediated cell–cell communication. MDR transfer from drug-resistant to drug-sensitive cells has been identified in several tumor entities. This was attributed, in some cases, to the direct shuttle of transporter molecules or its coding mRNA between cells. Also, EV-mediated transport of regulatory proteins (e.g., transcription factors) and noncoding RNAs have been indicated to induce MDR. Conversely, the transfer of a drug-sensitive phenotype via EVs has also been reported. Additionally, interactions between non-tumor cells and the tumor cells with an impact on MDR are presented. Finally, we highlight uninvestigated aspects and possible approaches to exploiting this knowledge toward the identification of druggable processes and molecules and, ultimately, the development of novel therapeutic strategies.